{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-25-001030","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.043965+00:00","generated_at":"2026-05-19T10:24:56.604745+00:00","sec_items":["1.0"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lexaria expands GLP-1-H24-4 trial with 5th tirzepatide arm","bullets":["Added 5th study arm investigating DehydraTECH-tirzepatide capsules in GLP1-H24-4 diabetes trial.","Existing four arms increased from 20 to 24 subjects; new arm will recruit 24 subjects.","Change Order with Novotech adds ~AU$1,900,000 to approved budget.","Human research ethics committee approval for the new arm was granted Feb 24, 2025.","Study evaluates DehydraTECH delivery of cannabidiol and GLP-1 agonists in pre/Type II diabetes."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-25-001030","json":"https://secwatch.observer/filing/0001640334-25-001030.json","markdown":"https://secwatch.observer/filing/0001640334-25-001030.md","text":"https://secwatch.observer/filing/0001640334-25-001030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033425001030/0001640334-25-001030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033425001030/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T10:24:56.604745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}